InvestorLens

SRTA — STRATA CRITICAL MEDICAL INC

Public company

Sign in to save4 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying SRTA?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 2 buying vs 0 selling last quarter
66
Macro Tailwind
Macro conditions are mixed for this sector
52
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their SRTA position last quarter, 2 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 52/100 in a Squeeze regime).

Supporting evidence
  • +2 tracked investors added or increased positions last quarter (Daniel Loeb, Cathie Wood)
  • +4 tracked investors reported holding SRTA at their latest filing
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/4/2026.

About STRATA CRITICAL MEDICAL INC (SRTA)

STRATA CRITICAL MEDICAL INC (SRTA) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Cathie Wood (ARK Investment Management), valued at $34M. Across recent filings, tracked investors recorded 3 new positions, 2 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in SRTA

100
/100
Strong Institutional Accumulation
Added / Increased5
Reduced0
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track SRTA

27
/100
Emerging Interest
4investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

SRTA Ownership Composition

How STRATA CRITICAL MEDICAL INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Growth Funds
58% of tracked value
Institutions
4
tracked investors
Total Reported
$54M
combined 13F value
Sectors3
  • Growth Funds57.7%
  • Hedge Funds39.2%
  • Other3.1%
Growth Funds(1)
57.7%
Hedge Funds(2)
39.2%
Other(1)
3.1%

Tracked investors reporting SRTA

  • Cathie WoodMar 31, 2026
    ARK Investment Management
    Shares
    7.5M
    Value
    $31.2M
    % Portfolio
    0.24%
  • Daniel LoebMar 31, 2026
    Third Point LLC
    Shares
    5M
    Value
    $20.9M
    % Portfolio
    1.00%
  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    402K
    Value
    $1.7M
    % Portfolio
    0.00%
  • Steve CohenMar 31, 2026
    Point72 Asset Management
    Shares
    67K
    Value
    $280.2K
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold SRTA?
4 tracked institutional investors disclosed a position in SRTA (STRATA CRITICAL MEDICAL INC) in their most recent 13F filing.
Who is the largest institutional holder of SRTA?
Cathie Wood, ARK Investment Management, holds the largest disclosed position in SRTA, valued at $34M.
Did institutional ownership of SRTA increase or decrease?
Across recent 13F filings, tracked investors recorded 3 new positions, 2 increased, 0 reduced, and 0 fully exited SRTA.
Where does this SRTA ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.